A study assessing factors that may determine a commercial health plan’s likelihood of covering a biosimilar found that biosimilars that are cancer therapies, used to treat children, indicated for highly prevalent conditions, or only competing against the originator were more likely to have coverage restrictions.
Coverage restrictions on biosimilars were observed in highly prevalent diseases but were less likely in biosimilars that generate an annual list price savings of more than $15,000 per patient.